Altro Health
Clinical infrastructure platform enabling wellness businesses to offer lab testing, prescriptions, and hormone services.
Website: https://altrohealth.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Altro Health |
| Tagline | Clinical infrastructure platform enabling wellness businesses to offer lab testing, prescriptions, and hormone services. |
| Headquarters | New York, United States [Altro Health, October 2026] |
| Founded | 2025 [Crunchbase] |
| Stage | Seed [Athletech News, October 2026] |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2), Andrea Corleto and Jennifer Arnold [Harvard Business School, retrieved 2026] |
| Funding Label | Seed |
| Total Disclosed Funding | ~$7,000,000 [Athletech News, October 2026] |
Links
Publicly reported
- Website: https://altrohealth.com/
- About: https://altrohealth.com/about
- How It Works: https://altrohealth.com/how-it-works
- Contact: https://altrohealth.com/contact
- Open Roles: https://apply.workable.com/altro/
- Podcast: https://tuesdayswithandrea.com/
Summary and Signal
PUBLIC Altro Health is building clinical infrastructure for wellness businesses, and it merits attention now because it paired a newly public seed round with a broad claim of nationwide availability in a category where compliance and operations are usually the bottleneck, not the demand signal [Athletech News, October 2026] [Altro Health Blog Post, October 2026] [Altro Health, retrieved 2026]. The company’s pitch is straightforward: help gyms, medspas, coaches, and other wellness operators add lab testing, prescriptions, peptides, and hormone-related services under their own brands, while Altro handles clinicians, pharmacy, and compliance behind the scenes [Altro Health, retrieved 2026] [NFX, June 2026].
The founding story appears to run through Lyv Health, a virtual longevity clinic previously operated by co-founders Andrea Corleto and Jennifer Arnold, which gives Altro a more credible origin than a purely conceptual software buildout [Harvard Business School, retrieved 2026] [Altro Health Blog Post, October 2026]. That matters because the product differentiation, based on public materials, is less about novel software and more about packaging clinical, regulatory, operational, and go-to-market support into a platform that can be sold on month-to-month terms to wellness businesses that do not want to assemble that stack themselves [Altro Health, retrieved 2026] [NFX, June 2026].
On team quality, the public record is directionally strong but still early. Corleto holds an MBA from Harvard Business School and has prior consumer health operating experience, including Lyv Health and Silkkin, while Arnold holds an MS/MBA from Harvard Business School and is described in public profiles as a biomedical engineer with operating experience in med-tech and FDA-related work [Harvard Business School, retrieved 2026] [Founded by Women, retrieved 2026] [Equilar ExecAtlas, retrieved 2026].
Capital formation is clearer than operating traction at this stage. Altro announced a $7 million seed round in October 2026 led by NFX, with participation from Founder Collective and Abby Miller Levy, and the company appears to be selling a B2B software-enabled services offering to wellness businesses rather than going direct to consumers [Athletech News, October 2026] [Altro Health Blog Post, October 2026].
The next 12 to 18 months will likely turn on evidence that the platform can convert broad category interest into durable customer adoption without compliance friction or customer concentration risk. Public materials cite availability in all 50 states and Washington, D.C., plus "thousands of users," but those claims remain company-sourced, and there are no named customers or independently verified deployment metrics in the public record reviewed here [Altro Health Blog Post, October 2026].
No independent source found -- This section mixes one independent funding report with company materials and founder-profile sources; key product breadth and traction claims remain company-sourced.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed ~$7,000,000 |
Company Overview
PUBLIC
Altro Health entered the public record in 2026 with a relatively clear wedge: it is building clinical infrastructure for wellness businesses that want to add services such as lab testing, prescriptions, and peptides without assembling the clinician, pharmacy, and compliance stack themselves [altrohealth.com] [Crunchbase]. The company is headquartered in New York, United States, and Crunchbase lists its founding year as 2025 [Crunchbase]. Its own site frames the business around helping wellness operators expand their offerings compliantly and under their own brands, which is a useful distinction because Altro appears to sell infrastructure to businesses rather than market care directly to end patients [altrohealth.com].
The origin story is partly visible through the founders' prior work. Harvard Business School identified Andrea Corleto and Jennifer Arnold as co-founders of Lyv Health before Altro, while Crunchbase currently points Altro's company profile through a Lyv Health organization page, suggesting some continuity between the earlier operating concept and the current platform company [Harvard Business School, retrieved 2026] [Crunchbase]. On Altro's own materials, the company positions that evolution as a response to what wellness businesses lacked: access to clinical tools, operational support, and compliant delivery rails for services clients were already seeking [altrohealth.com].
The key public milestone so far is financing. In October 2026, Altro announced a $7 million seed round led by NFX, with participation from Founder Collective and Abby Miller Levy, and Crunchbase reflects seed-stage funding for the business as well [Altro Health Blog Post, October 2026] [Crunchbase]. In the same period, the company presented itself as available across all 50 states and Washington, D.C., though that operating-footprint claim remains company-sourced and should be read with that limitation in mind [Altro Health Blog Post, October 2026].
One source, partially checked -- Core company facts are corroborated by Crunchbase and the company website, but milestone detail in this section relies partly on company-issued materials.
The Product and the Stack
MIXED
Altro is selling a fairly specific promise: let a wellness business add clinical services without standing up its own medical, pharmacy, and compliance machinery. On the company’s site, that translates into a platform for offering labs, prescriptions, and peptides under the customer’s own brand, with Altro handling clinicians, pharmacy, and compliance in the background [altrohealth.com] [altrohealth.com, October 2026]. The buyer profile described publicly is broad within wellness, spanning health coaches, medspas, wellness centers, fitness studios, and related owner-operator businesses rather than large health systems or payers [altrohealth.com] [nfx.com, June 2026].
The product surface, as publicly described, looks more like an infrastructure layer than a consumer app. Altro says it provides clinical, regulatory, operational, and software support so that customers can launch services on month-to-month terms and without long-term commitments, which suggests the company is trying to reduce both compliance burden and adoption friction for small businesses [altrohealth.com] [altrohealth.com, October 2026]. Athletech News and NFX both describe the offering through the same core use cases, blood testing, hormone-related services, prescriptions, and peptides, which gives the category definition some external corroboration even if the deeper workflow detail remains company-led [athletechnews.com, October 2026] [nfx.com, June 2026].
There is less public evidence on the underlying stack than on the commercial proposition, so any technical read has to stay narrow. A public Workable listing confirms active hiring for a senior software engineer and a founding product manager, which supports the view that Altro is building proprietary software rather than operating purely as a services intermediary, but the architecture, integrations, and data model are not described in the available public record [workable.com, retrieved 2026]. The same hiring footprint is consistent with an early product organization still being assembled, not a mature platform with a fully documented feature set (inferred from job postings) [workable.com, retrieved 2026].
No independent source found -- This section relies materially on company website claims, the company blog, and investor framing, with limited independent verification beyond Athletech News and Workable.
The Market They Are Entering
Publicly reported
This market matters now because Altro is selling into a part of wellness that is being pulled closer to regulated care, and that shift tends to reward infrastructure providers if demand broadens faster than operators can build compliance and clinical capacity themselves [Athletech News, October 2026] [NFX, June 2026].
The evidence base for market size is still thin in the public record. No named third-party TAM, SAM, or SOM study for Altro specifically appears in the materials reviewed, so any sizing discussion has to stay at the level of adjacent markets rather than pretend precision. Public sources do establish the target surface area: Altro positions itself around independent owner-operators and small wellness businesses such as health coaches, medspas, wellness centers, fitness studios, chiropractors, gyms, and personal trainers that want to add labs, prescriptions, peptides, and hormone services under their own brands [Altro Health, October 2026] [Altro Health] [Athletech News, October 2026]. That points to a broad but fragmented buyer base, which is commercially attractive if onboarding can be standardized, but also means market capture will depend less on one or two enterprise contracts and more on repeatable distribution into long-tail service businesses.
Demand drivers are clearer than market size. Across the company and investor materials, the recurring theme is that wellness operators see client demand for clinical-adjacent offerings but lack the infrastructure to deliver them compliantly on their own [Altro Health] [Altro Health, October 2026] [NFX, June 2026]. Altro's pitch is not just software, according to its website, it also covers clinicians, pharmacy, and compliance, which implies the product is aimed at reducing operational and regulatory friction rather than simply digitizing existing workflows [Altro Health]. The near-term tailwind is straightforward: if more coaches, trainers, and medspas want to monetize services like blood testing, prescriptions, peptides, and hormone support, an outsourced enablement layer becomes easier to justify than assembling each component independently [Athletech News, October 2026] [Altro Health].
Adjacent markets matter because they shape both budget availability and substitution risk. The closest public analogs in the source set are virtual longevity clinics and broader cash-pay wellness businesses. The founders previously operated Lyv Health, described in public materials as a virtual longevity clinic offering coaching, labs, hormone therapy, nutrition, and exercise support, and they present Altro as a response to the infrastructure gaps they encountered there [Harvard Business School, retrieved 2026] [Altro Health, October 2026] [NFX, June 2026]. That matters because Altro is not creating demand from scratch, it is trying to intermediate workflows that some operators may currently piece together through telehealth partners, pharmacies, medical directors, or point solutions. In practice, the substitute set is likely broader than any one software category, which can support demand but may complicate pricing and positioning.
Regulation is the central macro force in this category. The product claim itself is built around compliant access to clinical services, and Altro's public materials repeatedly emphasize handling clinicians, pharmacy, and compliance for customers [Altro Health] [Altro Health, October 2026]. That framing suggests the market opportunity expands when wellness businesses want to cross the line from content and coaching into regulated services, but it also means category growth is exposed to policy shifts around prescribing, telehealth practice structures, and fulfillment of products such as peptides and hormone-related therapies. The public record does not support a clean read on how resilient demand would be under tighter enforcement, so the prudent view is that market formation and regulatory interpretation are happening at the same time.
| Public market claim | What it indicates | Source |
|---|---|---|
| Altro targets health coaches, medspas, wellness centers, fitness studios, chiropractors, gyms, and personal trainers | Large, fragmented buyer universe across wellness SMBs | [Altro Health] [Altro Health] [Athletech News, October 2026] |
| Altro says it can help customers offer labs, prescriptions, and peptides under their own brands | Expansion from non-clinical wellness into clinical-adjacent revenue streams | [Altro Health] |
| NFX describes Altro as a "clinical Shopify for wellness" | Analog suggests an infrastructure-layer market rather than a single-service clinic model | [NFX, June 2026] |
| Altro says it is available in all 50 states and D.C. | If accurate, national reach materially widens addressable supply from launch | [Altro Health Blog Post, October 2026] |
The public market picture is directionally interesting but not yet numerically mature. What stands out is breadth of potential buyers and a plausible compliance-led wedge, while what remains missing is independent third-party sizing that would help distinguish a large durable category from an early demand pocket.
No independent source found -- This section relies primarily on company materials and investor commentary, with limited independent corroboration from Athletech News.
The Competitive Field
MIXED Altro is not competing head-on with a single software category so much as with the patchwork of telehealth vendors, pharmacy networks, compliance workflows, and in-house operational effort that wellness businesses would otherwise need to assemble themselves [Altro Health, October 2026] [NFX, June 2026] [Athletech News, October 2026].
The segment map is clearer than the current named-competitor record. On the public evidence, Altro sells to health coaches, medspas, gyms, personal trainers, wellness centers, and related owner-operators that want to add labs, prescriptions, peptides, and hormone-related services under their own brands [Altro Health] [Altro Health, October 2026] [NFX, June 2026]. That places its practical competition into three buckets: incumbent clinical infrastructure that already serves regulated care delivery, newer workflow platforms aimed at wellness-adjacent operators, and the do-it-yourself substitute of stitching together clinicians, pharmacy relationships, compliance support, and front-end software internally. No named direct competitors were confirmed in the supplied source set, and the public record reviewed by named publishers remains thin, so the competitive picture here rests more on category structure than company-by-company benchmarking [Athletech News, October 2026] [NFX, June 2026].
Altro's edge today appears to be packaging rather than scale. The company states that it handles clinicians, pharmacy, and compliance, and lets customers launch clinical services with month-to-month pricing and no long-term commitments, which lowers the adoption threshold for smaller wellness businesses that are not equipped to build regulated care operations themselves [Altro Health] [Altro Health]. NFX's description of Altro as a "clinical Shopify for wellness" points to the same thesis: the product is trying to abstract away clinical complexity for non-clinical operators [NFX, June 2026]. That edge is real if speed to launch and operational simplification matter more than deep customization, but it is also perishable. Packaging advantages are durable only if Altro builds dense provider, pharmacy, compliance, and customer workflow integrations that become hard to replicate or painful to switch away from.
The exposure is also visible in the same product design. Because Altro appears to sit at the regulated boundary between wellness and care delivery, better-capitalized telehealth infrastructure providers, pharmacy-aligned platforms, or specialized compliance operators could win on trust, breadth, or economics if they decide this buyer segment is worth pursuing. The absence of named public customers, deployment counts, or enterprise partnerships means there is not yet public evidence that Altro owns a distribution channel others cannot access [NFX, June 2026]. The company also does not appear, on the available sources, to control an end-consumer brand at scale, so its growth depends on enabling third-party operators rather than owning patient demand directly [Altro Health] [Athletech News, October 2026].
The most plausible 18-month scenario is a fragmented market in which the winner is whichever platform can convert regulatory complexity into a simple merchant-style operating layer for small wellness businesses. On current public evidence, Altro is a candidate winner if speed of onboarding, breadth across labs and prescriptions, and lightweight commercial terms prove more important than incumbent healthcare software depth [Altro Health] [NFX, June 2026]. The loser, if buyers decide they need established clinical credibility, broader care-delivery infrastructure, or vertically integrated distribution, is likely the stand-alone wellness infrastructure provider category itself rather than any one named company. Without named competitor disclosures or verified customer logos in the source set, that remains a conditional assessment rather than a settled market ranking.
Thinly sourced -- This section relies on company materials, an investor post, and one independent funding report; no named competitors were confirmed in the provided public sources, so the competitive map is partly inferential [Altro Health] [NFX, June 2026] [Athletech News, October 2026].
Opportunity
Upside Case
PUBLIC The prize here is not a better telehealth storefront, it is the chance to become the default clinical back end for thousands of wellness operators that want to add regulated care without becoming healthcare companies themselves [Altro Health, October 2026] [NFX, June 2026] [Athletech News, October 2026].
The headline opportunity is straightforward. If Altro can reliably let gyms, coaches, medspas, wellness centers, and similar operators launch labs, prescriptions, peptides, and hormone-related services under their own brands, then it sits in the transaction flow, compliance layer, and operating workflow for a category that has historically been fragmented and operationally difficult [Altro Health] [Altro Health, October 2026] [Athletech News, October 2026]. That outcome is reachable, not merely aspirational, because the company has already raised a $7 million seed led by NFX, has a live product marketed across all 50 states and D.C. according to the company, and is hiring across engineering and product, which suggests the buildout is underway rather than pre-launch concept work [Athletech News, October 2026] [Altro Health, October 2026] [Workable].
The public record supports a few distinct paths to scale, each with a different catalyst. The common thread is that Altro does not need to win the end consumer directly if it can become the infrastructure layer that wellness businesses depend on to add clinical revenue lines [Altro Health] [NFX, June 2026].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Branded care rails for independents | Altro becomes the standard operating layer for independent wellness businesses adding labs, prescriptions, and hormone-related services under their own brands | A repeatable onboarding motion for owner-operators in categories Altro already names, including health coaching, medspas, wellness centers, fitness studios, and chiropractor offices [Altro Health] | The product is explicitly designed for businesses that want to launch these services quickly while Altro handles clinicians, pharmacy, and compliance [Altro Health] [Altro Health, October 2026] |
| Embedded clinical commerce for fitness and wellness | Altro expands from service enablement into the checkout, retention, and reorder infrastructure behind recurring wellness programs | The category shift toward peptides, GLP-1-related programs, testing, and hormone services becoming a regular part of wellness offerings, as described by Athletech News and NFX [Athletech News, October 2026] [NFX, June 2026] | Altro's wedge is attached to monetizable, repeat-use services rather than one-time administrative tools, which gives the platform room to capture more workflow if adoption holds [Athletech News, October 2026] [Altro Health] |
| Compliance-first platform brand | Altro wins by being the trusted layer for clinical, regulatory, and operational support in a category where many wellness operators lack in-house infrastructure | A market preference for outsourced compliance and clinician management as smaller operators enter regulated services [Altro Health] [NFX, June 2026] | The company already positions its value around handling clinicians, pharmacy, compliance, and operations, which is a harder capability set to replace than simple front-end software [Altro Health] [Altro Health, October 2026] |
What compounding looks like is less about a classic consumer network effect and more about operating density. Each new wellness business onboarded gives Altro another distribution node for clinical services, another implementation pattern to standardize, and another reason to improve the shared infrastructure for clinician management, pharmacy coordination, compliance workflows, and software tooling [Altro Health] [Altro Health, October 2026]. If the company is already serving thousands of users, as it claims, that would suggest early evidence that the platform can aggregate demand across many downstream brands, even if named customers and retention figures are still absent from the public record [Altro Health, October 2026].
The second layer of compounding is brand abstraction. Altro's customers, not Altro, own the end-client relationship, which can make adoption easier if wellness operators want clinical services without ceding the customer to a third-party telehealth brand [Altro Health] [Athletech News, October 2026]. If that model works, distribution can scale through many small and midsize operators at once, and product breadth can raise account value over time as customers add new service lines instead of switching platforms.
The size of the win is therefore best framed through platform value rather than current disclosed revenue. NFX has described Altro as a "clinical Shopify for wellness," which is investor language rather than an operating fact, but the analogy is useful because the upside case depends on becoming infrastructure that many businesses build on top of, not a single consumer clinic chain [NFX, June 2026]. If Altro were to become a meaningful category platform for branded clinical enablement across wellness SMBs, the outcome could support venture-scale value creation in the hundreds of millions or higher (scenario, not a forecast), particularly because the company is trying to own a regulated workflow layer that is harder to displace than a point solution. The public evidence is still early, and there is no confirmed TAM study or public-market comp in the source set that would justify a tighter valuation range.
No independent source found -- This section relies materially on company and investor descriptions of product scope, customer categories, geographic coverage, and early usage, with limited independent corroboration beyond the reported seed round in Athletech News [Athletech News, October 2026] [Altro Health, October 2026] [NFX, June 2026].
Sources
Publicly reported
[Athletech News, October 2026] Startup That Lets Personal Trainers Offer Labs, Peptides & HRT Raises $7M | https://athletechnews.com/altro-health-startup-that-lets-personal-trainers-offer-labs-peptides-hrt-raises-7-million/
[Altro Health Blog Post, October 2026] Altro Health Raised $7M to Build the Clinical Infrastructure Wellness Businesses Need | https://altrohealth.com/post/altro-health-raised-7m-to-build-the-clinical-infrastructure-wellness-businesses-need
[Altro Health] Altro Health | The Clinical Infrastructure for Wellness Businesses | https://altrohealth.com/
[Crunchbase] Altro Health | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/lyv-health
[Harvard Business School, retrieved 2026] HBS Names Recipients of the 2026 Robert F. Jasse Distinguished Award in Entrepreneurship and Leadership | Newsroom | https://www.hbs.edu/news/releases/2026-jasse-award
[NFX, June 2026] 3 Reasons Why NFX Invested in Altro Health: A Clinical Shopify for Wellness | https://www.nfx.com/post/altro-health
[Founded by Women, retrieved 2026] Founded By Women | https://www.foundedbywomen.co/
[Equilar ExecAtlas, retrieved 2026] Jennifer Arnold | Equilar ExecAtlas | https://www.equilar.com/
[workable.com, retrieved 2026] Altro Health - Current Openings | https://apply.workable.com/altro/
[Workable] Altro Health - Current Openings | https://apply.workable.com/altro/
Articles about Altro Health
- Altro Health Wants to Be the Clinical Shopify for Wellness Coaches — Co-founders from Harvard Business School are building the regulatory and operational backend for a booming, but fragmented, longevity market.